Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30058051HIVENSG00000151577.14protein_codingDRD3NoNo1814A1A4V4
E9PCM4
P35462
X5D2G4
TVIS20057150HPVENSG00000151577.14protein_codingDRD3NoNo1814A1A4V4
E9PCM4
P35462
X5D2G4
TVIS20057354HPVENSG00000151577.14protein_codingDRD3NoNo1814A1A4V4
E9PCM4
P35462
X5D2G4
TVIS20040604HPVENSG00000151577.14protein_codingDRD3NoNo1814A1A4V4
E9PCM4
P35462
X5D2G4
TVIS44006680HTLV-1ENSG00000151577.14protein_codingDRD3NoNo1814A1A4V4
E9PCM4
P35462
X5D2G4
TCGA Plot Options
Drug Information
GeneDRD3
DrugBank IDDB01235
Drug NameLevodopa
Target IDBE0000581
UniProt IDP35462
Regulation Typeagonist
PubMed IDs18549347; 11978145; 9633680
CitationsOnofrj M, Bonanni L, Thomas A: An expert opinion on safinamide in Parkinson's disease. Expert Opin Investig Drugs. 2008 Jul;17(7):1115-25. doi: 10.1517/13543784.17.7.1115 .@@Deleu D, Northway MG, Hanssens Y: Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet. 2002;41(4):261-309.@@Koller WC, Rueda MG: Mechanism of action of dopaminergic agents in Parkinson's disease. Neurology. 1998 Jun;50(6 Suppl 6):S11-4; discussion S44-8. doi: 10.1212/wnl.50.6_suppl_6.s11.
GroupsApproved
Direct ClassificationTyrosine and derivatives
SMILESN[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
PathwaysTyrosine Metabolism; Disulfiram Action Pathway; Aromatic L-Aminoacid Decarboxylase Deficiency; Monoamine Oxidase-A Deficiency (MAO-A); Catecholamine Biosynthesis; Tyrosinemia, Transient, of the Newborn; Hawkinsinuria; Dopamine beta-Hydroxylase Deficiency; Tyrosinemia Type I; Alkaptonuria; Tyrosine Hydroxylase Deficiency
PharmGKBPA450213
ChEMBLCHEMBL1009